AbbVie’s Rinvoq shows long-term sustained efficacy in atopic dermatitis

AbbVie has released long-term efficacy and safety data from three Phase III trials investigating Rinvoq (upadacitinib) in moderate-to-severe atopic dermatitis.

The 140-week data analysis from Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422) and AD Up (NCT03568318) showed that 15mg and 30mg Rinvoq-treated patients achieved significantly higher skin clearance compared to the placebo cohort.